NVDA
NVIDIA Corporation
NVDA has the edge over PTRN overall, supported by stronger valuation and stronger modeled upside.
PTRN
Pattern Group Inc. Series A Common Stock
PTRN's outlook is improving, though it still trails on the overall score.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
PTRN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Stable | |
| Healthy |
PTRN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over PTRN in the historical PE scenario, which offers more potential upside but is not a forecast.
PTRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 24x | $18.66 | -11% |
| Fair | 25x | $19.54 | -6.7% |
| Expensive | 27x | $20.44 | -2.5% |
| Current | 27x | $20.95 | — |
| Forward | 28x | $20.95 | — |
Historical ranges are pointers, not guarantees.
PTRN's PE is 27x, but its earnings don't support one, so it isn't a reliable read right now.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
PTRN Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for PTRN, with profitability improving.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over PTRN on earnings, with more consistent year-over-year improvement.
PTRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.76 | -1.3% |
| Q3 2026 | $0.77 | +$2.68 |
| Q2 2026 | -$1.60 | -544% |
| Q1 2026 | -$1.66 | -603% |
| Q4 2025 | -$1.73 | -658% |
| Q3 2025 | -$1.91 | -782% |
PTRN has returned to profit: it earned $0.77 per share over the past year, after losing money the year before.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over PTRN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over PTRN on profitability, with a higher operating margin.
PTRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $885.8M | +38% |
| Q2 2026 | $876.8M | +47% |
| Q1 2026 | $773.7M | +43% |
| Q4 2025 | $723.1M | +40% |
| Q3 2025 | $639.7M | +46% |
| Q2 2025 | $598.2M | +39% |
| Q1 2025 | $540.4M | +32% |
| Q4 2024 | $515.5M | +31% |
PTRN's revenue has grown year over year every quarter since late 2024: $886M last quarter, up 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.2% | +14 points |
| Q2 2026 | 4% | -1 points |
| Q1 2026 | 5.1% | -0.3 points |
| Q4 2025 | 3.6% | -0.9 points |
| Q3 2025 | -9.4% | -13 points |
| Q2 2025 | 5% | -0.3 points |
| Q1 2025 | 5.4% | -0.2 points |
| Q4 2024 | 4.5% | +0.5 points |
PTRN's operating margin was 4.2% last quarter, up 14 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA's free cash flow has been positive every quarter for six years: $127B over the past year, up 76% from the year before.
PTRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $3.8M | +$7.1M |
| Q1 2026 | $63.3M | +47% |
| Q2 2025 | -$3.3M | -1297% |
| Q1 2025 | $43.2M | +26% |
PTRN generated $106M in free cash flow over the past year, up 42% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over PTRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
PTRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.2M shares |
| 1 year | +79% | +80.7M shares |
PTRN has 182M diluted shares, up 79% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $18.4M |
| Q2 2026 | $94,000 |
| Q1 2026 | $3.6M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q2 2024 | — |
| Q1 2024 | — |
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
PTRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.2x | Net Cash |
| Q2 2026 | -5.9x | Net Cash |
| Q1 2026 | -6.3x | Net Cash |
| Q4 2025 | -6.5x | Net Cash |
| Q3 2025 | -7.3x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -1.7x | Net Cash |
PTRN has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
PTRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 36.8 | Neutral |
PTRN's weekly RSI is 56 (neutral) and its Stochastic is 37 (neutral).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
PTRN PE vs Technology Sector
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
PTRN has stronger trend alignment. NVDA is above 1 of 5 weekly averages versus PTRN above 3 of 3.
PTRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.8 | 18% above |
| 20 week MA | $20.8 | 0.7% above |
| 50 week MA | $16.9 | 24% above |
PTRN is in an uptrend: it's above all three of its weekly moving averages, and 24% above its 50-week average.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.
PTRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $15.6 | $11.8 | -24% |
| 2026 YTD | $11.8 | $21.0 | +77% |
PTRN has the edge over NVDA on returns for 2026, with the stronger performance.